| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Institute of Anatomy, Christian-Albrechts-University of Kiel, Kiel, Germany.
PURPOSE. Recent studies have reported neuroprotective effects of erythropoietin (EPO) and vascular endothelial growth factor (VEGF). The purpose of the present study was to clarify their influence on neurite outgrowth and regeneration of rat retinal ganglion cells (RGCs) in vitro and to elucidate the expression of corresponding receptors in the rat retina in vivo.
METHODS. Retinal explants from postnatal rats were stimulated with VEGF alone; VEGF in combination with anti-VEGF-receptor (VEGF-R)-2 antibody or T-type Ca2+ channel blocker ethosuximide (ESX); EPO alone; or EPO in combination with anti-EPO-receptor antibody or ESX. The presence of the corresponding receptors in the rat retina was assessed by reverse transcription-polymerase chain reaction (RT-PCR) and by immunohistochemistry.
RESULTS. EPO induced a stable improvement of neurite outgrowth of RGCs in a dose-dependent manner (5 x 10-15 M to 5 x 10-13 M) up to 169% (P < 0.05). Treatment of the explants with anti-EPO-R antibody (1:80 dilution) and with ESX (5 µM) totally inhibited EPO-mediated effects on RGCs. In comparison, VEGF (50 ng/mL), induced neurite outgrowth of retina explants up to 167% (P < 0.05), which again was inhibited in the presence of anti-VEGF-R2 antibody or ESX. Transcripts of EPO-R, VEGF-R1, and VEGF-R2 were detected by RT-PCR. Intense immunoreactivity for VEGF-R1, VEGF-R2, and EPO-R were found in the RGC layer of the retina.
CONCLUSIONS. The data demonstrate for the first time that EPO and VEGF have a significant and specific biological effect on neurite regrowth of axotomized RGCs. Therefore, these results imply that EPO and VEGF have not only a neuroprotective but also a neuroregenerative role in ischemic retinal conditions.
This article has been cited by other articles:
|
|
 |
|
  B. Avci, R. Avci, U. U. Inan, and B. Kaderli Comparative Evaluation of Apoptotic Activity in Photoreceptor Cells after Intravitreal Injection of Bevacizumab and Pegaptanib Sodium in Rabbits Invest. Ophthalmol. Vis. Sci., July 1, 2009; 50(7): 3438 - 3446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ruiz de Almodovar, D. Lambrechts, M. Mazzone, and P. Carmeliet Role and Therapeutic Potential of VEGF in the Nervous System Physiol Rev, April 1, 2009; 89(2): 607 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bartels, K. Spate, H. Krampe, and H. Ehrenreich Review: Recombinant human erythropoietin: novel strategies for neuroprotective/neuroregenerative treatment of multiple sclerosis Therapeutic Advances in Neurological Disorders, November 1, 2008; 1(3): 193 - 206. [Abstract] [PDF]
|
|
|
|
|
|
C. Q. Yu, M. Zhang, K. I. Matis, C. Kim, and M. I. Rosenblatt Vascular Endothelial Growth Factor Mediates Corneal Nerve Repair Invest. Ophthalmol. Vis. Sci., September 1, 2008; 49(9): 3870 - 3878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhang, Y. Wu, Y. Jin, F. Ji, S. H. Sinclair, Y. Luo, G. Xu, L. Lu, W. Dai, M. Yanoff, et al. Intravitreal Injection of Erythropoietin Protects both Retinal Vascular and Neuronal Cells in Early Diabetes Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 732 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nishijima, Y.-S. Ng, L. Zhong, J. Bradley, W. Schubert, N. Jo, J. Akita, S. J. Samuelsson, G. S. Robinson, A. P. Adamis, et al. Vascular Endothelial Growth Factor-A Is a Survival Factor for Retinal Neurons and a Critical Neuroprotectant during the Adaptive Response to Ischemic Injury Am. J. Pathol., July 1, 2007; 171(1): 53 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. D'Amore Vascular Endothelial Cell Growth Factor-A: Not Just for Endothelial Cells Anymore Am. J. Pathol., July 1, 2007; 171(1): 14 - 18. [Full Text] [PDF]
|
|
|
|
|
|
L. Zhong, J. Bradley, W. Schubert, E. Ahmed, A. P. Adamis, D. T. Shima, G. S. Robinson, and Y.-S. Ng Erythropoietin Promotes Survival of Retinal Ganglion Cells in DBA/2J Glaucoma Mice Invest. Ophthalmol. Vis. Sci., March 1, 2007; 48(3): 1212 - 1218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ding, M. Scortegagna, R. Seaman, D. G. Birch, and J. A. Garcia Retinal Disease in Mice Lacking Hypoxia-Inducible Transcription Factor-2{alpha} Invest. Ophthalmol. Vis. Sci., March 1, 2005; 46(3): 1010 - 1016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Weishaupt, G. Rohde, E. Polking, A.-L. Siren, H. Ehrenreich, and M. Bahr Effect of Erythropoietin Axotomy-Induced Apoptosis in Rat Retinal Ganglion Cells Invest. Ophthalmol. Vis. Sci., May 1, 2004; 45(5): 1514 - 1522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Weiss New Insights Into Erythropoietin and Epoetin Alfa: Mechanisms of Action, Target Tissues, and Clinical Applications Oncologist, December 1, 2003; 8(90003): 18 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Li, W. Cao, and R. E. Anderson Alleviation of Constant-Light-Induced Photoreceptor Degeneration by Adaptation of Adult Albino Rat to Bright Cyclic Light Invest. Ophthalmol. Vis. Sci., November 1, 2003; 44(11): 4968 - 4975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Rakic, V. Lambert, L. Devy, A. Luttun, P. Carmeliet, C. Claes, L. Nguyen, J.-M. Foidart, A. Noel, and C. Munaut Placental Growth Factor, a Member of the VEGF Family, Contributes to the Development of Choroidal Neovascularization Invest. Ophthalmol. Vis. Sci., July 1, 2003; 44(7): 3186 - 3193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Becerra and J. Amaral Erythropoietin -- An Endogenous Retinal Survival Factor N. Engl. J. Med., December 12, 2002; 347(24): 1968 - 1970. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
